Eli Lilly Expands Neuroscience Portfolio with Centessa Pharmaceuticals Acquisition

Eli Lilly and Company, a leading pharmaceutical giant known for its innovative healthcare solutions, is progressing to expand its neuroscience portfolio through the acquisition of Centessa Pharmaceuticals plc. This strategic acquisition, announced on March 31, 2026, positions Lilly to enhance its capabilities in developing treatments specifically for sleep-wake disorders.

A Closer Look at Centessa Pharmaceuticals

Centessa Pharmaceuticals is a clinical-stage organization focused on developing a new class of medications that address excessive daytime sleepiness and other neurological conditions. Their work revolves around orexin receptor 2 (OX2R) agonists, which are therapeutics developed to target the critical neurobiological systems related to the sleep-wake cycle. Among its promising pipeline, the investigational drug cleminorexton (previously known as ORX750) has shown significant potential during Phase 2a clinical trials, particularly for conditions such as narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

The compelling research and findings surrounding Centessa's OX2R agonist portfolio suggest possible applications in a wider array of neurological and psychiatric disorders. This potential broad-spectrum advantage emphasizes the significance of Lilly’s decision to merge capabilities with Centessa, as it promises to unlock innovative treatment options for patients struggling with severe sleep disorders.

Strategic Implications of the Acquisition

According to Carole Ho, Executive Vice President and President of Lilly Neuroscience, the underlying biology of orexin receptors presents one of the most fascinating opportunities in neuroscience today. The collaboration is anticipated to accelerate the development of successful treatment solutions across various neurological conditions, signaling a potential shift in therapeutic approaches for sleep-wake disruption.

Mario Alberto Accardi, the CEO of Centessa, expressed excitement regarding this acquisition, highlighting that their portfolio's uniqueness could help reshape the current paradigms within the neuroscience field. The union between Centessa’s innovative practices with Lilly’s robust research capabilities is expected to foster rapid advancements in orexin-based therapeutics. The combined strengths will be invaluable in ensuring faster delivery of life-changing medications to those in critical need of assistance.

Financial Aspects of the Deal

Under the terms, the transaction involves Lilly acquiring all shares of Centessa at a rate of $38.00 per share in cash, in addition to a contingent value right (CVR) that offers the potential for up to $9.00 based on achieving specific milestones tied to regulatory approvals. This brings the total possible equity value to approximately $47.00 per share. The total cash upfront consideration is approximately $6.3 billion, with an additional potential equity value of around $1.5 billion derived from the CVRs.

This major acquisition is projected to close in the third quarter of 2026, pending necessary approvals from Centessa shareholders and regulatory authorities. The move represents a significant premium of about 40.5% compared to Centessa's trading price prior to the announcement.

Looking Ahead: The Future of Neuroscience at Lilly

As Lilly embarks on this new chapter, the implications are substantial not only for the company but for the broader medical community involved with sleep and neurological disorders. The consolidation aims to push the boundaries of what treatments can achieve and offers hope for millions who rely on effective solutions for conditions that affect their quality of life.

For patients and healthcare professionals alike, this merger signals a commitment to advancing innovative research and developing powerful therapeutic options. Lilly's strategic vision promises to harness the cutting-edge science behind orexin receptor biology not only to enhance wakefulness but also to transform the landscape of neuroscience treatments as a whole.

In conclusion, as Eli Lilly integrates Centessa Pharmaceuticals into its operations, the future looks brighter for those battling sleep-wake disorders and related neurological challenges. The pooling of resources and knowledge between these two powerhouses of medicine is set to yield groundbreaking results in patient care and medical science.